Pharmafile Logo

White paper helps industry navigate new NHS roadmap

August 24, 2020 | Covid-19 recovery, NHS Reset 

New report shows how pharma can support the NHS in the Covid-19 recovery era

As the pandemic response in the UK moves on to ‘phase 3’, and the NHS plans to make a gradual return to pre-Covid-19 service levels, pharma must define how its products and services fit into the new roadmap that has been created.

In a bid to answer some of these questions for industry, healthcare intelligence provider Wilmington Healthcare has published a white paper, entitled “Covid-19: Roadmap to Recovery”.

The white paper looks at the next stages in the recovery process for the NHS and explores how industry can support the health service as it faces a multitude of challenges, including dealing with the care backlog and Covid-19 aftercare.

It covers three major areas, the first two of which are the NHS Reset initiative and its attendant policies; followed by the status and aims of the various NHS stakeholders tasked with taking the service through the next phase.

It also tackles issues surrounding NHS recovery from the point of view of pharma and defines the issues that are affecting it from access and digital engagement to the role of new NHS pathways.

The need to respond at scale and pace to the coronavirus pandemic has created unprecedented collaboration between the NHS and pharma in areas such as protection of supply chains and rapid development of Covid-19 drugs and vaccines. The challenge now is to maintain and strengthen partnership working.

Oli Hudson, Content Director at Wilmington Healthcare and one of the authors of the white paper, saidAs the NHS resets, it will require innovation, technology, new pathways and new solutions to the various issues emerging from Covid-19. Industry needs to identify the right stakeholders and develop propositions tailored to their changing needs.

“With the right brand strategy and approach, some very promising new partnerships can be formed. This white paper aims to give industry powerful insights into the opportunities that are emerging and help it define how to support the NHS through the challenges that lie ahead.”

To register to download the free white paper visit http://ow.ly/yY3C30r5auA

Ends

This content was provided by Wilmington Healthcare

Company Details

 Latest Content from  Wilmington Healthcare 

How will Sustainability and Transformation Plans (STPs) change the NHS commissioning landscape?

Sue Thomas and Paul Midgley, of Wilmington Healthcare, take a look at new commissioning structures and what they mean for pharma

New report shows Traumatic Brain Injury (TBI) is a major threat to older people

A report by healthcare intelligence provider Wilmington Healthcare and the charity, United Kingdom Acquired Brain Injury Forum (UKABIF), shows that many hospital admissions in England for Traumatic Brain Injury (TBI)...

How will Sustainability and Transformation Plans (STPs) change the NHS in 2017?

Sue Thomas and Paul Midgley, of Wilmington Healthcare, assess the impact that STPs will have on the NHS and what this means for pharma.

How can pharma help the NHS drive much-needed change in mental health services?

Laurence Mascarenhas, of Wilmington Healthcare, assesses how pharma can help the NHS to achieve Parity of Esteem (PoE) in mental health

How can the NHS deliver integrated care?

Sue Thomas and Paul Midgley, of Wilmington Healthcare, explain the changes needed to help the NHS provide a more holistic, joined up experience for patients

How can pharma engage with NHS Vanguards?

Sue Thomas and Paul Midgley, of Wilmington Healthcare, explore the opportunities for pharma to help NHS vanguards develop new models of care.

What does the Five Year Forward View mean for pharma?

Sue Thomas and Paul Midgley, of Wilmington Healthcare, assess how the Five Year Forward View (5YFV) is changing the NHS and how pharma can get involved in redesigning NHS services.